Latest Us Market Growth News

ARB Corporation Limited reported a 5.3% increase in sales revenue to $729.9 million for FY2025, driven by strong export growth and steady domestic sales, while profit after tax declined 5%. The company declared a special fully franked dividend amid ongoing US expansion efforts.

Oneview Healthcare reported a robust 36% revenue increase in H1 2025, driven by US market growth and the launch of its AI-powered Care Assistant, Ovie. Operational restructuring and AI innovation underpin its strategy for scalable, efficient deployments.

The Calmer Co. has secured a long-term lease for its Navua facility in Fiji, replacing a planned property purchase and freeing up capital to accelerate its US market expansion.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

BetMakers Technology Group capped FY25 with its strongest quarterly results ever, showcasing record profitability, positive cash flow, and a debt-free balance sheet. The company’s strategic investments and recent capital raise set the stage for accelerated growth in FY26, including a key acquisition in Nevada.

Xero has completed a significant A$1.85 billion institutional placement to fund its acquisition of Melio, aiming to enhance its accounting and payments platform in the US market. A complementary A$200 million Share Purchase Plan will offer retail investors a chance to participate.

QuickFee Limited has launched a A$1.5 million capital raising to fund expansion of its loan books in the US and Australia, following a quarter of record revenue and positive earnings before tax. The fintech also completed a major refinancing and revised its earnings guidance due to a credit impairment provision.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.